Merck & Co Inc. (MRK) on Tuesday announced that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) currently being studied in 15 Phase 3 trials for multiple cancers, including breast, endometrial, and lung cancers.
Under the terms of the deal, Blackstone will provide $700 million to help fund a portion of sac-TMT's development costs through 2026. In exchange, Blackstone will be eligible for low-to-mid single-digit royalties on net sales of sac-TMT across Merck's marketing territories, contingent upon U.S. regulatory approval for first-line treatment of triple-negative breast cancer based on results from the TroFuse-011 clinical trial.
"This agreement positions Merck to harness the potential of sac-TMT, a promising ADC candidate targeting TROP2, while we continue to advance our broad and expansive pipeline," said Caroline Litchfield, chief financial officer, Merck.
Merck shares closed Monday at $82.49, down 4.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.